Monoamine oxidase inhibitors

Bibliography

• SHIH JC, CHEN K, RIDD MJ: Monoamine oxidase: from genes to behavior. Annu. Rev. Neurosci. (1999) 22:197-217. Provides a brief summary on the general properties of MAOs and a comprehensive account on the use of MAO-A and MAO-B gene knockout mice to establish links between MOA-A and MOA-B activities and selected animal behaviours.
   Google Scholar
• ABELL CW, KWAN SW: Molecular characterization of monoamine oxidases A and B. Frog. Nucleic Acid Res. Mot. Biol. (2001) 65:129–156.
   PubMedGoogle Scholar
• BENEDETTI MS: Biotransformation of xenobiotics by amine oxidases. Fundam. Clin. PharmacoL (2001) 15:75–84.
   PubMed Web of Science ®Google Scholar
• KALGUTKAR AS, DALVIE DK, CASTAGNOLI N Jr et al.: Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors. Chem. Res. Toxicol (2001) 14:1139–1162.
   Google Scholar
• ••A comprehensive review on the interactions of nitrogen-containing xenobiotics with MA0s, with emphasis on the potential relationships between metabolism and pharamacological activity.
   Google Scholar
• BACH AW, LAN NC, JOHNSON DL et al.: cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc. NatL Acad. ScL USA (1988) 85:4934–4938.
   PubMed Web of Science ®Google Scholar
• LAN NC, CHEN CH, SHIH JC: Expression of functional human monoamine oxidase A and B cDNAs in mammalian cells../. Neurochem. (1989) 52: 1652-1654.
   Google Scholar
• JOHNSTON JP: Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol (1968) 17:1285–1297.
   PubMed Web of Science ®Google Scholar
• FOWLER CJ, ORELAND L, CALLINGHAM BA: The acetylenic monoamine oxidase inhibitors clorgyline, deprenyl, pargyline and J-508: their properties and applications. Pharm. Pharmacol (1981) 33:341–347.
   PubMed Web of Science ®Google Scholar
• KNOLL J, MAGYAR K: Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv. Biochem. Psychopharmacol. (1972) 5:393–408.
   PubMedGoogle Scholar
• CHEN K, SHIH J: Monoamine oxidase type A and B: structure, function and behaviour. Adv. Pharmacol (1998) 42:292–296.
   PubMedGoogle Scholar
• TIPTON KF, O'CARROLL AM, McCRODDEN JM: The catalytic behavior of monoamine oxidase. Neural Tranvia. (1987) 23S:25–35.
   Google Scholar
• CASES O, SEIF I, GRIMSBY J et al: Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAO A. Science (1995) 268:1763–1766.
   PubMed Web of Science ®Google Scholar
• KIM JJ, SHIH JC, CHEN K et al.: Selective enhancement of emotional, but not motor, learning in monoamine oxidase A-deficient mice. Proc. Nati Acad. Sci USA (1997) 94:5929–5933.
   PubMedGoogle Scholar
• GRIMSBY J, TOTH M, CHEN K et al.: Increased stress response andl3-phenylethylamine in MAO-B deficient mice. Nat. Genet. (1997) 17:1–5.
   PubMedGoogle Scholar
• SQUIRES RF: Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species. Adv. Biochem. Pharmacol (1972) 5:355–369.
   PubMedGoogle Scholar
• GARRICK NA, MURPHY DL: Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain. Psychopharmacology (1980) 72:27–33.
   PubMedGoogle Scholar
• KRUEGER MG, MAZOUZ F, RAMSAY RR et al.: Dramatic species differences in the susceptibility of monoamine oxidase B to a group of powerful inhibitors. Biochem. Biophys. Res. Commun. (1995) 206:556–562.
   PubMed Web of Science ®Google Scholar
• O'BRIEN E, DOSTERT P, TIPTON KF: Species differences in the interactions of anticonvulsants milacemide and some analogs with monoamine oxidase B. Biochem. Pharmacol (1995) 50:317–324.
   PubMedGoogle Scholar
• BINDA C, NEWTON-VINSON P, HUBALEK F et al.: Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat. Smart. Biol (2002) 9:22–26.
   PubMedGoogle Scholar
• ••The authors reported the first X-raystructure of the complex of MAO-B and the MAO-B selective inhibitor selegeline. This new information provides an important tool for future structure-based new drug design.
   Google Scholar
• MABIC S, CASTAGNOLI N Jr: Assessment of structural requirements for the monoamine oxidase-B-catalyzed oxidation of 1,4-disubstituted-1,2,3,6-tetrahydropyridine derivatives related to the neurotoxin 1-methy1-4-pheny1-1,2,3,6-tetrahydropyridine. I Med. Chem. (1996) 39:3694–3700.
   PubMed Web of Science ®Google Scholar
• NANDIGAMA RK, EDMONDSON DE: Structure-activity relations in the oxidation of phenylethylamine analogues by recombinant human liver monoamine oxidase A. Biochemistry(2000) 39:15258–15265.
   PubMedGoogle Scholar
• MILLER JR, EDMONDSON DE: Structure-activity relationships in the oxidation of para-substituted benzylamine analogues by recombinant human liver monoamine oxidase A. Biocehmismy (1999) 38:13670–13683.
   PubMedGoogle Scholar
• ROBITZEK EH, SELIKOFF IJ, ORNSTEIN GG: Chemotherapy of human tuberculosis with hydrazine derivatives of isonicotinic acid. Q. Bull. Sea View Hosp. (1952) 13:27–51.
   PubMedGoogle Scholar
• ZELLER EA, BARDSKY J: In vivo inhibition of liver and brain monoamine oxidase by 1-isonicotiny1-2-isopropyl-hydrazine. Proc. Soc. Exp. Biol. (1952) 81:459–461.
   PubMed Web of Science ®Google Scholar
• O'CONNOR JB, HOWLETT KS, WAGNER RR: Side effects accompanying use of iproniazid. Am. Rev 7itherc. (1953) 68:270–272.
   Google Scholar
• LOOMER HP, SAUNDERS JC, KLINE NS: A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Am. Psychiam Assoc. Psychiatric Res. Rep. (1957) 8:129–141.
   PubMedGoogle Scholar
• KLINE NS: Monoamine oxidase inhibitors: An unfinished picaresque tale. In: Discoveries M Biological Psychiatry Ayd FJ, Blackwell B (Eds), Lippincott, Philadelphia, USA (1970): 194–204.
   Google Scholar
• MEDICAL RESEARCH COUNCIL: Clinical trial of the treatment of depressive illness. Br. Med. (1965) 251:881–886.
   Google Scholar
• KLEIN DF, GITTELMAN R, QUITKIN F et al.: Diagnosis and treatment of psychiatric disorders: adults and children, 2nd Ed., Williams & Wilkins, Baltimore (1980).
   Google Scholar
• WEST ED, DALLY P: Effects of iproniazidon depressive syndromes. Br. Med. j (1959) 1:1491–1494.
   PubMed Web of Science ®Google Scholar
• ROBINSON DS, NIES A, RAVARIS CL et al.: The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive-anxiety states. Arch. Gen. Psychiat. (1973) 29:407–413.
   PubMed Web of Science ®Google Scholar
• PARE CMB: The present status of monoamine oxidase inhibitors. Br. Psychiat. (1985) 146:576–584.
   PubMedGoogle Scholar
• QUITKIN FM, RIFKIN A, KLEIN DF: Monoamine oxidase inhibitors: a review of antidepressant effectiveness. Arch. Gen. Psychiat. (1979) 36:749–760.
   PubMed Web of Science ®Google Scholar
• LOTUFO-NETO F, TRIVEDI M, THASE M: Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology (1999) 20:226–247.
   PubMed Web of Science ®Google Scholar
• CALNE DB: Drug therapy: treatment of Parkinson's disease. N Engl. I Med. (1993) 329:1021–1027.
   PubMed Web of Science ®Google Scholar
• ZHAO Z, DALVIE D, NAIMAN N et al: Design, synthesis, and biological evaluation of novel 4-subsituted 1-methyl-12,3,6-tetrahydropyridine analogs of MPTP Med. Chem. (1992) 35:4473–4478.
   Google Scholar
• KALGUTKAR AS, CASTAGNOLI N Jr, TESTA B: Selective inhibitors of monoamine oxidase (MAO-A and MAO-B) as probes of its catalytic site and mechanism. Med. Res. Rev (1995) 15:325–388.
   PubMed Web of Science ®Google Scholar
• ••An extensive and comprehensively writtenreview on MAOIs.
   Google Scholar
• WALSH BT, STEWART JW, ROOSE SP et al.: Treatment of bulimia with phenelzine. Arch. of Gen. Psychiat. (1984) 41:1105–1109.
   PubMed Web of Science ®Google Scholar
• DAVIDSON J, RAFT D: Monoamine oxidase inhibitors in patients with chronic pain. Arch. Gen. Psychiat. (1985) 42:635–636.
   PubMedGoogle Scholar
• JENIKE MA, SURMAN OS, CASSEM NH et al.: Monoamine oxidase inhibitors in obsessive compulsive disorder. Psychiat. (1983) 44:131–132.
   Google Scholar
• ZAMETKIN A, RAPOPORT JL, MURPHY DL et al Treatment of hyperactive children with monoamine oxidase inhibitors. Arch. Gen. Psychiat. (1985) 42:962–977.
   PubMed Web of Science ®Google Scholar
• PAUL H, WENDER MD: Pharmacotherapy of attention-deficit/ hyperactivity disorder in adults. ./. Clin. Psychiat (1998) 59:76S–79S.
   Google Scholar
• WYATT RJ, POTKIN SJ, MURPHY DL: Platelet monoamine oxidase activity in schizophrenia: a review of the data. Am. Psychiat. (1979) 136:377–385.
   PubMed Web of Science ®Google Scholar
• YU PH, BOWEN RC, DAVIS BA et al.: Platelet monoamine oxidase activity and trace acid levels in plasma of agoraphobic patients. Acta Psychiat. Scand. (1983) 78:188–194.
   Google Scholar
• VON KNORRING AL, ORELAND L, WINBLAD B: Personality traits related to monoamine oxidase (MAO) activity in platelets. Psychiat. Res. (1984) 12:11–26.
   PubMed Web of Science ®Google Scholar
• VON KNORRING AL, HALLMAN J, VON KNORRING L et al.: Platelet monoamine oxidase activity in type 1 and type 2 alcoholism. A/coho/A/cohoL (1991) 26:409–416.
   Google Scholar
• COURSEY RD, BUCHSBAUM MS, MURPHY DL: Platelet MAO activity and evoked potentials in the identification of subjects biologically at risk for psychiatric disorders. Br. Psychiat. (1979) 134:372–381.
   PubMed Web of Science ®Google Scholar
• SIMS KB, DE LA CHAPELLE A, NORIO R et al.: Monoamine oxidase deficiency in males with an X chromosome deletion. Neurons (1989) 2:1069–1076.
   Google Scholar
• FORD MF: Treatment of depression in Huntington's disease with monoamine oxidase inhibitors. Brit. I Psychiat. (1986) 149:654–656.
   PubMed Web of Science ®Google Scholar
• MARKIANOS M, SFAGOS C, BISTOLAKI E: Platelet monoamine oxidase and plasma dopamine-beta-hydroxylase activities in patients with multiple sclerosis. Acta Neuro. Scand. (1991) 84:531–533.
   PubMedGoogle Scholar
• MAZZINI L, TESTA D, BALZARINI C et al.: An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis. Neurol (1994) 241:223–227.
   Web of Science ®Google Scholar
• MYLLYLA VV, SOTNIEMI KA, VUORINEN JA et al.: Selegiline as initial treatment in de novo Parkinsonian patients. Neurology (1992) 42:339–343.
   PubMed Web of Science ®Google Scholar
• TARIOT PN, COHEN R, SUNDERLAND T et al.: L-Deprenyl in Alzheimer's disease. Arch. Gen. Psychiat. (1987) 44:427–433.
   PubMed Web of Science ®Google Scholar
• TARIOT PN, SUNDERLAND T, WEINGARTNER H et al.: Cognitive effects of L-Deprenyl in Alzheimer's disease. Psychophannacology (1987) 91:489–495.
   PubMedGoogle Scholar
• KUHN W, MULLER TH: The clinical potential of deprenyl in neurological and psychiatric disorders. I Neural Transm. (1996) 48:85–93.
   Google Scholar
• EBADI M: Therapeutic potential of selegiline in Parkinson's disease and other neurological disorders. In: Recent advances in neurodegenerative disorders. Marwah J, Teitelbaum H (Eds), Prominent Press, Scottsdale, AZ (1998):256–350.
   Google Scholar
• KIM H, SABLIN SO, RAMSAY RR: Inhibition of monoamine oxidase A by 13-carboline derivatives. Arch. Biochem. Biophys. (1997) 337:137–142.
   PubMed Web of Science ®Google Scholar
• MEDVEDEV AE, GOODWIN B, CLOW A et al.: Inhibitory potency of some isatin analogues on human monoamine oxidase A and B. Biochem. PhannacoL (1992) 44:590–592.
   PubMed Web of Science ®Google Scholar
• FINK DM, PALERMO MG, BORES GM et al: Imino1,2,3,4-tetrahydrocyclopent[B]indole carbamates as dual inhibitors of acetylcholinesterase and monoamine oxidase. Bioorg. Med. Chem. Lett. (1996) 6:625–630.
   Web of Science ®Google Scholar
• HARFENIST M, McGEE, DPC, WHITE HL: A selective, reversible, competitive inhibitor of monoamine oxidase A containing no nitrogen with negligible potential of tyramine induced blood pressure rise.' Med. Chem. (1991) 34:2931–2933.
   Google Scholar
• HARFENIST M, JOYNER CT, MIZE PD et al.: Selective inhibitors of monoamine oxidase 2 Arylamide SAR. I Med. Chem. (1994) 37:2085–2089.
   PubMedGoogle Scholar
• HARFENIST M, McGEE DPC, REEVES MD et al.: Selective inhibitors of monoamine oxidase (MAO). 5. 1-substituted phenoxathiin inhibitors containing no nitrogen that inhibit MAO A by binding it to a hydrophobic site.' Med. Chem. (1998) 41:2118–2125.
   Google Scholar
• TIPTON KF, MCCRODDEN JM, KALIR AS et al.:Inhibition of rat liver monoamine oxidase by alpha-methyl- and N-propargyl-amine derivatives. Biochem. Pharmacol (1982) 31:1251–1255.
   PubMed Web of Science ®Google Scholar
• ULUS IH, MAHER TJ, WURTMAN RJ: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem. Pharmacol (2000) 59:1611–1621.
   PubMed Web of Science ®Google Scholar
• KINEMUCHI H, ARAI Y, TOYOSHIMA Y et al.: Studies on 5-fluoro- a-methyltryptamine and p-chloro-P-methylhphenylethylamine. Determination of the MAO-A and MAO-B selective inhibition M vitro. fpn. I Pharmacol (1988) 46:197–199.
   Google Scholar
• JEGHAM S, GEORGE P: Monoamine oxidase A and B inhibitors. Exp. Opin. Ther. Patents (1998) 8(9):1143–1150.
   Web of Science ®Google Scholar
• MARUYAMA W, YAMAMOTO T, KITANI K et al.: Mechanism underlying anti-apoptotic activity of a O deprenyl-related propargylamine, rasagiline. Mech. Ageing Dev. (2000) 116:181–191.
   PubMed Web of Science ®Google Scholar
• WEINSTOCK M, GOREN T, YOUDIM MBH: Development of a novel neuroprotective drug (TV3326) for the treatment of Alzheimer's disease, with cholinesterase and monoamine oxidase inhibitory activities. Drug Dev. Res. (2000) 50:216–222.
   Web of Science ®Google Scholar
• WEINSTOCK M, POLTYREV T, BEJAR C et al: Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression. Psychopharmacology (2002) 160:318–324.
   PubMedGoogle Scholar
• •In both reference 68 and 69, the authors provide a detailed account of research and development on aminoindan derivatives for the treatment of Alzheimer's disease.
   Google Scholar
• BOULTON AA: Symptomatic and neuroprotective properties of the aliphatic propargylamines. Mech. Ageing Dev. (1999) 111:201–209.
   PubMedGoogle Scholar
• CLEMETT D, MARKHAM A: Linezolid. Drugs (2000) 59:815–827.
   PubMed Web of Science ®Google Scholar
• THULL U, KNEUBUHLER S, GAILLARD P et al.:Inhibition of monoamine oxidase by isoquinoline derivatives. Biochem. Pharmacol (1995) 50:869–877.
   PubMedGoogle Scholar
• NAOI M, NAGATSU T: Quinoline and quinaldine as naturally occurring inhibitors specific for type A monoamine oxidase. Life Sci. (1987) 40:1075–1082.
   PubMedGoogle Scholar
• BEMBENEK ME, ABELL CW, CHRISEY LA et al.: Inhibition of monomine oxidases A and B by simple isoquinoline alkaloids: racemic and optically active 1, 2,3,4-tetrahydro-, 3,4-dihydro-, and fully aromatic isoquinolines. Med. Chem. (1990) 33:147–152.
   Google Scholar
• AZIZ SA, KNOWLES CO: Inhibition of monoamine oxidase by the pesticide chlordimeform and related compounds. Nature (1973) 242:417–418.
   PubMed Web of Science ®Google Scholar
• LOCKHART B, CLOSIER M, HOWARD K et al: Differential inhibition of [3H]-oxotremorine-M and [3H]-quinuclinidyl benzilate binding to muscarinic receptors in rat brain membranes with acetylcholinesterase inhibitors. Naunyn Scluniedebergs Arch. Phannacol (2001) 363:429–438.
   PubMed Web of Science ®Google Scholar